Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement Settlement Agreement On February 17, 2026, Protagenic Therapeutics, Inc. (“PTIX” or the “Company”) entered into a Set
Termination of a Material Definitive Agreement As described above, upon the Closing of the Unwind Agreement on February 17, 2026, the SEA dated May 15, 2025 was
Completion of Acquisition or Disposition of Assets On February 17, 2026, pursuant to the Unwind Agreement, PTIX disposed of its ownership interest in Phytanix B
Unregistered Sales of Equity Securities The return and cancellation of shares of PTIX common stock issued pursuant to the SEA were effected pursuant to the Unwi
Other Events The Settlement Agreement resolves all claims asserted in the Litigation and provides for dismissal of the action with prejudice. Item 9.01 Financia